On May 6, 2025, Zoetis Inc. (NYSE: ZTS), the global leader in animal health, officially released its first quarter financial results for 2025, showcasing robust growth and resilience in an evolving economic landscape. This report provides an authoritative, data-driven insight into Zoetis’ financial performance, operational highlights, and updated outlook for the full year, contextualized with insights from prior earnings calls.
Zoetis, headquartered in Parsippany, New Jersey, announced for Q1 2025 total revenue of \(2.22 billion, reflecting a 1% increase compared to the same quarter in 2024. On an organic operational basis—excluding foreign exchange effects and portfolio adjustments—the revenue grew a notable 9%. Net income for the quarter was \)631 million, an increase of 5% year-over-year, while diluted earnings per share (EPS) rose 8% to \(1.41 per share. Adjusted net income climbed 4% to \)662 million, with adjusted diluted EPS at $1.48, marking a 7% increase on a reported basis and 8% on an organic operational basis. This strong start to 2025 builds on historical momentum, supported by a diversified portfolio and strategic agility.
Zoetis manages commercial operations via two primary segments: United States (U.S.) and International markets. In Q1 2025: - U.S. Segment: Generated revenue of \(1.18 billion (+2%), driven by 6% organic operational growth. Sales of companion animal products surged 8%, fueled by flagship products like Simparica Trio®, Apoquel®, Cytopoint®, Librela®, and Solensia®. Livestock products declined 21% on reported basis reflecting portfolio divestitures but only 2% on an organic basis. - **International Segment:** Posted flat reported revenue at \)1.0 billion but an impressive 11% organic operational increase. Companion animal product sales grew 10% operationally, supported by innovations and approvals, while livestock product sales rebounded 12% organically.
Simparica Trio® received new U.S. label indication for flea tapeworm prevention and approval in South Korea.
Revolution® Plus attained new approval in the U.K. for additional efficacy claims.
Advanced recombinant vector vaccines for poultry received regulatory approvals in the U.S., Canada, EU, Brazil, and the U.K.
The 1% revenue bump, when compared to the substantial \(9.26 billion revenue base for FY 2024, demonstrates Zoetis' resilient expansion trajectory amid macroeconomic challenges like fluctuating foreign exchange rates and tariff enactments. For full year 2025, Zoetis updated revenue guidance to \)9.425 billion - \(9.575 billion, forecasting 6% to 8% organic operational growth. Adjusted net income is projected between \)2.775 billion and $2.825 billion, guided by 5% to 7% operational organic growth amid enacted tariffs.
###Forward-Looking Commentary CEO Kristin Peck emphasizes, “Zoetis achieved strong results for the first quarter of 2025, driven by demand for our innovative products and our focus on delivering for our customers. These results reinforce the essential nature of our business and the preference for our innovative products.” This aligns with previous earnings call themes highlighting Zoetis’ strategic focus on innovative companion animal care and diversified market presence.
Zoetis’ Q1 2025 results exhibit a stable growth pattern with strong revenue and earnings expansion, driven notably by companion animal products and strategic innovations. The company’s updated guidance underscores its commitment to navigating foreign exchange and tariff headwinds while maintaining operational growth. Industry stakeholders and investors should track Zoetis’ continued advances in product innovation and geographic expansion in 2025.
For further details, access the source document here.
Keywords: Zoetis financial results Q1 2025, Zoetis revenue growth, Zoetis net income, Zoetis organic operational growth, Zoetis companion animal products, Simparica Trio approval, Zoetis livestock segment, Zoetis financial guidance, Kristin Peck commentary
Tags: Zoetis Q1 2025 Results, Companion Animal Innovation, Organic Revenue Growth, Veterinary Pharmaceutical Market, Tariff Impact Analysis